Nomura analyst Christopher Marai maintained a Sell rating on Alnylam Pharma (ALNY – Research Report) today and set a price target of $75.00. The company’s shares closed last Monday at $131.67, close to its 52-week high of $133.00.
According to TipRanks.com, Marai is a 4-star analyst with an average return of 5.2% and a 50.0% success rate. Marai covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Protagonist Therapeutics, and Alexion Pharmaceuticals.
Alnylam Pharma has an analyst consensus of Strong Buy, with a price target consensus of $141.25.
The company has a one-year high of $133.00 and a one-year low of $65.81. Currently, Alnylam Pharma has an average volume of 712.2K.
Based on the recent corporate insider activity of 25 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ALNY in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Alnylam Pharmaceuticals, Inc. operates as biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. It is the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics for the treatment of genetically defined diseases.